Tetsuro Matano

Prof. Tetsuro Matano

National Institute of Infectious Diseases
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in iScience
Verified
Journal Article
Open access
HOHirofumi Ohashi
Hirofumi Ohashi
KWKoichi Watashi
Koichi Watashi
WSWakana Saso
Wakana Saso
KSKaho Shionoya
Kaho Shionoya
SIShoya Iwanami
Shoya Iwanami
TWTakaji Wakita
Takaji Wakita
Antiviral treatments targeting the coronavirus disease 2019 are urgently required. We screened a panel of already-approved drugs in a cell culture model of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and identified two new agents having higher antiviral potentials than the drug candidates such as Remdesivir and Chroloquine in VeroE6/TMPRSS2 cells: the anti-inflammatory drug Cepharanthine and HIV protease inhibitor Nelfinavir. Cepharanthine inhibited SARS-CoV-2 entry through the blocking of viral binding to target cells, whilst Nelfinavir suppressed viral replication partly by protease inhibition. Consistent with their different modes of action, synergistic effect of this combined treatment to limit SARS-CoV-2 proliferation was highlighted. Mathematical modeling in vitro antiviral activity coupled with the calculated total drug concentrations in the lung predicts that Nelfinavir will shorten the period until viral clearance by 4.9-days and the combining Cepharanthine/Nelfinavir enhanced their predicted efficacy. These results warrant further evaluation of the potential anti-SARS-CoV-2 activity of Cepharanthine and Nelfinavir.

3 September 2021 in Microbiology Spectrum
Verified
Journal Article
Open access
AIAya Ishizaka
Aya Ishizaka
MKMichiko Koga
Michiko Koga
TMTaketoshi Mizutani
Taketoshi Mizutani
PPPrince Kofi Parbie
Prince Kofi Parbie
DPDiki Prawisuda
Diki Prawisuda
HYHiroshi Yotsuyanagi
Hiroshi Yotsuyanagi
Chronic inflammation is a hallmark of HIV infection and is associated with the development and progression of age-related comorbidities. Although the gastrointestinal tract is a major site of HIV replication and CD4+T-cell depletion, the role of HIV-associated imbalance of gut microbiome in chronic inflammation is unclear.

27 April 2022 in Microbiology Spectrum
Verified
Journal Article
Open access
TMTaketoshi Mizutani
Taketoshi Mizutani
AIAya Ishizaka
Aya Ishizaka
MKMichiko Koga
Michiko Koga
KIKazuhiko Ikeuchi
Kazuhiko Ikeuchi
MSMakoto Saito
Makoto Saito
HYHiroshi Yotsuyanagi
Hiroshi Yotsuyanagi
There is growing evidence that the commensal microbiota of the gastrointestinal and respiratory tracts regulates local and systemic inflammation (gut-lung axis). COVID-19 is primarily a respiratory disease, but the involvement of microbiota changes in the pathogenesis of this disease remains unclear.

19 January 2022 in Cell Reports Medicine
Verified
Journal Article
Open access
HIHiroshi Ishii
Hiroshi Ishii
TNTakushi Nomura
Takushi Nomura
HYHiroyuki Yamamoto
Hiroyuki Yamamoto
MNMasako Nishizawa
Masako Nishizawa
THTrang Thi Thu Hau
Trang Thi Thu Hau
TMTetsuro Matano
Tetsuro Matano
Effective vaccines are essential for the control of the coronavirus disease 2019 (COVID-19) pandemic. Currently developed vaccines inducing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-antigen-specific neutralizing antibodies (NAbs) are effective, but the appearance of NAb-resistant S variant viruses is of great concern. A vaccine inducing S-independent or NAb-independent SARS-CoV-2 control may contribute to containment of these variants. Here, we investigate the efficacy of an intranasal vaccine expressing viral non-S antigens against intranasal SARS-CoV-2 challenge in cynomolgus macaques. Seven vaccinated macaques exhibit significantly reduced viral load in nasopharyngeal swabs on day 2 post-challenge compared with nine unvaccinated controls. The viral control in the absence of SARS-CoV-2-specific NAbs is significantly correlated with vaccine-induced, viral-antigen-specific CD8+ T cell responses. Our results indicate that CD8+ T cell induction by intranasal vaccination can result in NAb-independent control of SARS-CoV-2 infection, highlighting a potential of vaccine-induced CD8+ T cell responses to contribute to COVID-19 containment.

18 May 2021 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PPPrince Kofi Parbie
Prince Kofi Parbie
TMTaketoshi Mizutani
Taketoshi Mizutani
AIAya Ishizaka
Aya Ishizaka
AKAi Kawana-Tachikawa
Ai Kawana-Tachikawa
LRLucky Ronald Runtuwene
Lucky Ronald Runtuwene
TMTetsuro Matano
Tetsuro Matano
HIV-1 infected individuals under antiretroviral therapy can control viremia but often develop non-AIDS diseases such as cardiovascular and metabolic disorders. Gut microbiome dysbiosis has been indicated to be associated with progression of these diseases. Analyses of gut/fecal microbiome in individual regions are important for our understanding of pathogenesis in HIV-1 infections. However, data on gut/fecal microbiome has not yet been accumulated in West Africa. In the present study, we examined fecal microbiome compositions in HIV-1 infected adults in Ghana, where approximately two-thirds of infected adults are females. In a cross-sectional case-control study, age- and gender-matched HIV-1 infected adults (HIV+; n = 55) and seronegative controls (HIV-; n = 55) were enrolled. Alpha diversity of fecal microbiome in HIV+ was significantly reduced compared to HIV- and associated with CD4 counts. HIV+ showed reduction in varieties of bacteria including Faecalibacterium, the most abundant in seronegative controls, but enrichment of Proteobacteria. Ghanaian HIV+ exhibited enrichment of Dorea and Blautia; bacteria groups whose depletion has been reported in HIV-1 infected individuals in several other cohorts. Furthermore, HIV+ in our cohort exhibited a depletion of Prevotella, a genus whose enrichment has recently been shown in men having sex with men (MSM) regardless of HIV-1 status. The present study revealed the characteristics of dysbiotic fecal microbiome in HIV-1 infected adults in Ghana, a representative of West African populations.

15 December 2014 in Journal of Virology
Verified
Journal Article
Open access
PDF file
KTKazutaka Terahara
Kazutaka Terahara
HIHiroshi Ishii
Hiroshi Ishii
TNTakushi Nomura
Takushi Nomura
NTNaofumi Takahashi
Naofumi Takahashi
ATAkiko Takeda
Akiko Takeda
TMTetsuro Matano
Tetsuro Matano
CD4+T-cell responses are crucial for effective antibody and CD8+T-cell induction following virus infection. However, virus-specific CD4+T cells can be preferential targets for human immunodeficiency virus (HIV) infection. HIV-specific CD4+T-cell induction by vaccination may thus result in enhancement of virus replication following infection. In the present study, we show that vaccine-elicited CD4+T cells expressing CD107a are relatively resistant to depletion in a macaque AIDS model. Comparison of virus-specific CD107a, macrophage inflammatory protein-1β, gamma interferon, tumor necrosis factor alpha, and interleukin-2 responses in CD4+T cells of vaccinated macaques prechallenge and 1 week postchallenge showed a significant reduction in the CD107a−but not the CD107a+subset after virus exposure. Those vaccinees that failed to control viremia showed a more marked reduction and exhibited significantly higher viral loads at week 1 than unvaccinated animals. Our results indicate that vaccine-induced CD107a−CD4+T cells are depleted following virus infection, suggesting a rationale for avoiding virus-specific CD107a−CD4+T-cell induction in HIV vaccine design.IMPORTANCEInduction of effective antibody and/or CD8+T-cell responses is a principal vaccine strategy against human immunodeficiency virus (HIV) infection. CD4+T-cell responses are crucial for effective antibody and CD8+T-cell induction. However, virus-specific CD4+T cells can be preferential targets for HIV infection. Here, we show that vaccine-induced virus-specific CD107a−CD4+T cells are largely depleted following infection in a macaque AIDS model. While CD4+T-cell responses are important in viral control, our results indicate that virus-specific CD107a−CD4+T-cell induction by vaccination may not lead to efficient CD4+T-cell responses following infection but rather be detrimental and accelerate viral replication in the acute phase. This suggests that HIV vaccine design should avoid virus-specific CD107a−CD4+T-cell induction. Conversely, this study found that vaccine-induced CD107a+CD4+T cells are relatively resistant to depletion following virus challenge, implying that induction of these cells may be an alternative approach toward HIV control.